Clinical Trials Logo

HBV Carrier clinical trials

View clinical trials related to HBV Carrier.

Filter by:
  • None
  • Page 1

NCT ID: NCT02953600 Recruiting - HBV Carrier Clinical Trials

Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration

Start date: November 2016
Phase: N/A
Study type: Interventional

Hepatocellular carcinoma (HCC) is a very severe disease in Taiwan caused 7,000 deaths per year, and majorly about 70% is caused by the chronic hepatitis B virus infection. A repeat, long-term, and severe chronic hepatitis would be more possible progressed into liver cirrhosis and HCC. As previous records, there might be 2% of chronic HBV patient would progress to liver cirrhosis, and 5% of the liver cirrhosis's patients would develop to HCC. In some cases, the HBV patient also might directly develop to HCC without liver cirrhosis phase.